Reading view
Advanced iPSC-based modelling of LMNA-related congenital muscular dystrophy enables development of genetic therapies for muscle laminopathies
Leveraging host-cell modulators of adeno-associated vector transduction to tailor viral biodistribution
In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells
A combinatorial EV-miRNA signature mediates the anti-tumoral activity of NFAT3-regulated extracellular vesicles in aggressive cancers
Tissue-specific silencing of synthetic mRNAs by de-targeting elements maps vaccination-competent tissues and allows Cas9 de-immunization
Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice
Repurposing base editors for targeted knockin and simultaneous multiplex knockouts to generate allo-CAR T cells with minimal translocations
Repurposing triamterene as chloride intracellular channel 1 inhibitor via ligand-based approach for glioblastoma
Teacher Geometry Shapes Learnability in Teacher-Student Networks
HiRAD: A Flexible Large-Scale AGV Routing System
Zero-shot World Models Are Developmentally Efficient Learners
PRIME-SVR: Physics-infoRmed Implicit Multi-Echo Slice-to-Volume Reconstruction for Fetal T2 mapping
Investigating Hyperparameter Optimization and Transferability for ES-HyperNEAT: A TPE Approach
When Does a Laugh Begin? Structured Annotator Disagreement in Temporal Laughter Localization
Omni Interaction Agent Technical Report
“Small” Large Language Models in the Hospital: Evaluation Study on Real-World Data in a Resource-Constrained Setting
Innovative pathological and therapeutic approaches for poorly cohesive gastric cancer
Front Oncol. 2026 Aug 25;16:1842715. doi: 10.3389/fonc.2026.1842715. eCollection 2026.
ABSTRACT
Poorly cohesive gastric cancer (PCGC) represents a biologically distinct subtype of gastric cancer, characterized by diffuse growth, marked intratumoral heterogeneity, and a consistently worse prognosis compared with other histological subtypes. Despite advances in pathological classification and molecular profiling, treatment strategies remain largely independent of histological subtype, and no specific therapeutic approaches have been established for PCGC. In this review, we summarize current evidence on the biological features, diagnostic challenges, and emerging therapeutic strategies, with a focus on novel targeted agents and innovative treatment platforms. Recent years have witnessed the development of therapies directed against specific molecular targets, including HER2, PD-L1, CLDN18.2, FGFR2b, and TROP2, as well as the introduction of antibody-drug conjugates and bispecific antibodies, progressively expanding the therapeutic landscape of gastric cancer. However, their clinical impact in poorly cohesive tumors remains to be fully defined. In parallel, advances in digital pathology, artificial intelligence, and multi-omics approaches are providing new opportunities to improve diagnostic reproducibility, refine prognostic stratification, and support personalized treatment strategies by integrating histomorphological and molecular tumor features. Overall, the convergence of novel therapeutic strategies and advanced diagnostic technologies may pave the way toward a more precise and biologically informed management of PCGC, although further validation and integration into clinical practice are required.
PMID:42713041 | PMC:PMC13550965 | DOI:10.3389/fonc.2026.1842715
Innovative pathological and therapeutic approaches for poorly cohesive gastric cancer
Front Oncol. 2026 Aug 25;16:1842715. doi: 10.3389/fonc.2026.1842715. eCollection 2026.
ABSTRACT
Poorly cohesive gastric cancer (PCGC) represents a biologically distinct subtype of gastric cancer, characterized by diffuse growth, marked intratumoral heterogeneity, and a consistently worse prognosis compared with other histological subtypes. Despite advances in pathological classification and molecular profiling, treatment strategies remain largely independent of histological subtype, and no specific therapeutic approaches have been established for PCGC. In this review, we summarize current evidence on the biological features, diagnostic challenges, and emerging therapeutic strategies, with a focus on novel targeted agents and innovative treatment platforms. Recent years have witnessed the development of therapies directed against specific molecular targets, including HER2, PD-L1, CLDN18.2, FGFR2b, and TROP2, as well as the introduction of antibody-drug conjugates and bispecific antibodies, progressively expanding the therapeutic landscape of gastric cancer. However, their clinical impact in poorly cohesive tumors remains to be fully defined. In parallel, advances in digital pathology, artificial intelligence, and multi-omics approaches are providing new opportunities to improve diagnostic reproducibility, refine prognostic stratification, and support personalized treatment strategies by integrating histomorphological and molecular tumor features. Overall, the convergence of novel therapeutic strategies and advanced diagnostic technologies may pave the way toward a more precise and biologically informed management of PCGC, although further validation and integration into clinical practice are required.
PMID:42713041 | PMC:PMC13550965 | DOI:10.3389/fonc.2026.1842715
Breaking timescales with generative sampling of conformational transitions
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-11025-1
A generative committor-guided path-sampling framework reconstructs rare biomolecular transition pathways and reveals the underlying thermodynamics and kinetics without using predefined collective variables or brute-force sampling, at an acceptable computational cost.